Skip to content
Search

Latest Stories

Essential Pharma appoints ex Accord executive as general counsel

Essential Pharma has announced the appointment of Andrew Webb as general counsel, EVP Legal and Compliance in the UK.

With significant global pharmaceutical corporate and mergers and acquisitions experience, Andrew joined Essential's senior management team in the UK as general counsel.


Prior to joining Essential Pharma, Andrew spent over three years at Accord Healthcare where he worked as UK & Ireland general counsel and associate vice president of Legal Transactions for EMENA.

Starting his career at Linklaters, a leading multinational law firm, Andrew spent over 11 years managing numerous global transactions both at home and abroad in the pharmaceutical sector.

During his time at Linklaters, his global knowledge of the life science industry was established, including during over nine months in Switzerland working with Novartis on secondment and approximately two years in Linklaters’ New York office.

Andrew has a BA in Law from the University of Oxford and is a trustee for the charity London Playing Fields Foundation.

Steen Vangsgaard, CEO of Essential Pharma, commented: “I am thrilled to welcome Andrew as our new General Counsel and look forward to leveraging his knowledge of global markets as we accelerate our commercial efforts. Andrew’s proven operational and commercial expertise will be invaluable to the senior management team as we scale-up and further expand our product portfolio with the potential to substantially improve the lives of patients.

“Essential Pharma is at a pivotal time in its development as it further expands its product portfolio and looks to grow to new international patient populations,” added Andrew Webb. “The company has built a compelling portfolio of products and continues to gather momentum to provide therapies where there is a high unmet medical need. I very much look forward to working with the team to capitalise on business opportunities and deliver value to patients, payers and our business owners.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less